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146A Randomized, Controlled Trial of the Effect
of Allopurinol on Left Ventricular Mass
Index in Hemodialysis PatientsElaine Rutherford1,2, Sheila Ireland3, Kenneth Mangion1, Graham A. Stewart4,
Mark S. MacGregor5, Giles Roditi1,6, Rosemary Woodward1, Stephen J. Gandy7,8,
J. Graeme Houston8, Alan G. Jardine1,2, Petra Rauchhaus9, Miles D. Witham10,
Patrick B. Mark1,2 and Allan D. Struthers3
1Institute of Cardiovascular and Medical Sciences, BHF Clinical Research Centre, University of Glasgow, UK; 2Renal &
Transplant Unit, Queen Elizabeth University Hospital, NHS Greater Glasgow & Clyde, Glasgow, UK; 3Division of Molecular &
Clinical Medicine, School of Medicine, Ninewells Hospital, University of Dundee, Dundee, UK; 4Renal Unit, Ninewells Hospital,
NHS Tayside, Dundee, UK; 5Renal Unit, Crosshouse Hospital, NHS Ayrshire & Arran, Kilmarnock, UK; 6Department of Radi-
ology, Glasgow Royal Infirmary, NHS Greater Glasgow & Clyde, Glasgow, UK; 7Department of Radiology, Ninewells Hospital,
NHS Tayside, Dundee, UK; 8Medical Physics, Ninewells Hospital, NHS Tayside, Dundee, UK; 9Tayside Clinical Trials Unit,
School of Medicine, Ninewells Hospital, University of Dundee, Dundee, UK; and 10NIHR Newcastle Biomedical Research
Centre, Newcastle University and Newcastle upon Tyne Hospitals Trust, Campus for Ageing and Vitality, Newcastle upon Tyne,
UKIntroduction: Increased left ventricular mass index (LVMI) is associated with mortality in end-stage renal
disease. LVMI regression may improve outcomes. Allopurinol has reduced LVMI in randomized controlled
trials in chronic kidney disease, diabetes, and ischemic heart disease. This study investigated whether
allopurinol would regress LVMI in hemodialysis patients.
Methods: This was a randomized placebo-controlled double-blind multicenter trial funded by the British
Heart Foundation (PG/12/72/29743). A total of 80 patients undergoing regular maintenance hemodialysis
were recruited from NHS Tayside, NHS Greater Glasgow and Clyde and NHS Ayrshire and Arran in
Scotland, UK. Participants were randomly assigned on a 1:1 ratio to 12 months of therapy with allopurinol
300 mg or placebo after each dialysis session. The primary outcome was change in LVMI, as assessed by
cardiac magnetic resonance imaging (CMRI) at baseline and 12 months. Secondary outcomes were
change in BP, flow-mediated dilation (FMD), augmentation indices (AIx), and pulse wave velocity (PWV).
Results: A total of 53 patients, with a mean age of 58 years, completed the study and had CMRI follow-up
data for analysis. Allopurinol did not regress LVMI (change in LVMI: placebo þ3.6  10.4 g/m2;
allopurinol: þ1.6  11 g/m2; P ¼ 0.49). Allopurinol had no demonstrable effect on BP, FMD, AIx, or PWV.
Conclusion: Compared with placebo, treatment with allopurinol did not regress LVMI in this trial.
Kidney Int Rep (2021) 6, 146–155; https://doi.org/10.1016/j.ekir.2020.10.025
KEYWORDS: allopurinol; hemodialysis; left ventricular mass; magnetic resonance imaging; randomized controlled trial
ª 2020 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).P
remature cardiovascular death is the leading cause
of death among hemodialysis patients. Left ven-
tricular hypertrophy (LVH) is extremely common in
these patients, present in 74% of patients commencing
dialysis.1 Increased left ventricular mass (LVM) is
strongly associated with all-cause and cardiovascular
mortality.2,3 Increased LVM in patients with chronicspondence: Elaine Rutherford, Institute of Cardiovascular &
al Sciences, BHF Clinical Research Centre, 126 University
Glasgow, G12 8TA, UK. E-mail: elaine.rutherford@glasgow.
ved 15 June 2020; revised 1 October 2020; accepted 20
er 2020; published online 4 December 2020kidney disease (CKD) has consistently been shown to be
associated with adverse outcomes2,4; it is therefore
plausible that reduction of LVM may reduce cardio-
vascular morbidity and mortality, although this has
been more challenging to demonstrate.5
Multiple randomized trials have focused on reduc-
tion of LVM in patients receiving hemodialysis as a
potential therapeutic target.6–9 Although some studies
have achieved reduction in LVM, this has often
involved a significant lifestyle alteration for patients,
for example, nocturnal or frequent hemodialysis.9,10
Some drug therapies, such as angiotensin-converting
enzyme inhibitors, angiotensin receptor blockers, and
potassium-sparing diuretics, have potential benefit inKidney International Reports (2021) 6, 146–155
E Rutherford et al.: A Randomized Trial of Allopurinol in Hemodialysis CLINICAL RESEARCHattenuating LVH11 but have side effects, such as
hyperkalemia, which are particularly unwelcome in the
hemodialysis population. Therefore, additional and
alternative therapeutic strategies to target LVH are
required. Allopurinol has been in clinical use for more
than 50 years, and although traditionally used to lower
uric acid and therefore reduce recurrent gout episodes,
it has novel properties that make it a potentially
attractive tool in the battle against LVH. Firstly,
increased oxidative stress and endothelial dysfunction
are hallmarks of end-stage kidney disease (ESKD) and
hemodialysis.12,13 Allopurinol has been shown to pro-
foundly reduce oxidative stress and to improve endo-
thelial function in multiple populations.14–17 Secondly,
arterial stiffness is a feature of ESKD that further con-
tributes to LVH and cardiovascular risk, and allopu-
rinol has been shown to ameliorate this.18,19
Furthermore, in a population with CKD stage 3, allo-
purinol regressed LVMI, improved endothelial func-
tion, and improved central AIx when compared to
placebo.18
Allopurinol has been shown to reduce LVMI in
randomized controlled trials in chronic CKD stage 3,18
diabetes,20 and ischemic heart disease,17 but until
now no study had examined its use in hemodialysis. As
well as having a more severe stage of kidney disease,
patients undergoing hemodialysis are subject to many
more complex hemodynamic, metabolic, and inflam-
matory insults than their counterparts who have early
CKD. It was therefore unknown whether allopurinol
would still be able to regress LVH in this more extreme
condition. We therefore investigated whether allopu-
rinol might regress LVMI in a population undergoing
hemodialysis by conducting a multicenter, double-
blind, randomized, placebo-controlled trial.
METHODS
Study Design
This was a 12-month, placebo-controlled, randomized,
double-blind, multicenter, parallel group trial. All pa-
tients provided consent to participate. This trial was
conducted in adherence to the Declaration of Helsinki
and was approved by the East of Scotland Ethics
Committee (13/ES/0051) and the UK Medicine and
Healthcare Products Regulatory Authority (2013-
001436-22). The trial was publicly registered
(clinicaltrials.gov NCT01951404).
Study Population
Subjects receiving hemodialysis therapy for ESKD in
NHS Ayrshire & Arran, NHS Tayside and NHS
Greater Glasgow and Clyde, Scotland, UK, were
randomized between January 2014 and June 2015.
Participants had been receiving hemodialysis forKidney International Reports (2021) 6, 146–155more than 3 months and were more than 18 years of
age.
Patients were excluded if any of the following
criteria were present: known heart failure (ejection
fraction <45%); already on allopurinol, known to have
an adverse reaction to it, or to have active gout; ma-
lignancy, severe hepatic disease, or other life-
threatening condition; on azathioprine, 6-
metacaptopurine, or theophylline; had a planned kid-
ney transplant; in another clinical study (other than
observational or registry) within the last 30 days; un-
able to give informed consent; pregnant or breast-
feeding; contraindication to magnetic resonance
imaging; or any other serious illness or significant ab-
normalities that may have compromised their safety or
successful participation in the study. To optimize
study recruitment without impeding study integrity, a
number of amendments were made to these criteria
during the course of the study (see Supplementary
Methods).
Trial Intervention
After baseline assessments, participants were randomly
assigned to receive either an allopurinol 100 mg or
placebo capsule 3 times weekly after hemodialysis for 2
weeks. If this dose was tolerated, it was then escalated
weekly to 200 mg, 250 mg, then up to the maximum
dose of 300 mg which was the optimal dose determined
in a dose finding study.21 Participants then continued
on this dose, or the maximum tolerated dose, for the
duration of the trial. Follow-up visits at dialysis ses-
sions were conducted at 6 weeks, 6 months, and 9
months (Supplementary Figure S1). Cardiac magnetic
resonance imaging (CMRI) on a post-dialysis day was
performed prior to randomization and following 12
months of treatment.
Study Outcomes
The primary study outcome was to determine whether
allopurinol induced a change in CMRI-measured LVMI
in patients with ESKD when compared to placebo.
Secondary outcomes of this study were as follows: (i) to
determine whether there was a change in left ventric-
ular end-systolic volume (LVESV), left ventricular end-
diastolic volume (LVEDV), or left ventricular ejection
fraction (LVEF) with allopurinol when compared to
placebo; (ii) to determine whether there was a differ-
ence in endothelial function with allopurinol compared
with placebo, measured by flow-mediated dilation
(FMD) and augmentation indices (AIx); and (iii) to
assess whether there were changes in blood pressure
(BP) control as measured by clinic (dialysis) BP and 24-
hour BP monitoring with allopurinol compared with
placebo.147
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All participants underwent CMRI on a post-dialysis
day prior to randomization and following 12 months
of treatment on a 3.0 Tesla magnetic resonance imaging
scanner (MAGNETOM, Verio/Trio, Siemens Health-
care, Erlangen, Germany). Full CMRI methods are
described in the Supplementary Methods.
Other Trial Parameters
Flow-mediated dilation, radio-carotid pulse wave ve-
locity (PWV), and radial AIx were optional components
of the trial that were performed at baseline, month 9,
and month 12 of the trial. All FMD was carried out in
accordance with the International Brachial Artery
Reactivity Task Force guidelines.22,23
Blood pressure taken as a part of standard care was
available for analysis; participants could also undergo
optional 24-hour ambulatory BP monitoring at baseline
and after 12 months of treatment.
Blinding and Randomization
This was a double-blind trial; investigators and par-
ticipants were blinded to treatment allocations. Block
randomization was on a 1:1 ratio and was undertaken
by Tayside Pharmaceuticals, who used Random-
ization.com (www.randomization.com) to create
randomization blocks of 4. Medication was pre-labeled
with a sequential study number and distributed to
local clinical trial pharmacies. Medication was then
distributed from there in sequence according to order
of randomization.
Sample Size Calculation
Grothues et al. proposed that CMRI studies of LVH
regression should be powered for a 10-g change in LV
mass (4.8g/m2 change in LVMI).24 A previous study
using spironolactone in CKD found a reduction in LV
mass of 10  12 g.25 Based on these values, 32 patients
would be required per group to have 90% power with
a ¼ 0.05 to detect this change in LV mass. A 10%
death or transplantation rate per year and a 10%
dropout rate for the trial were originally expected;
therefore, we planned to recruit 76 participants.
Withdrawals during the trial were more common than
originally anticipated; thus, 4 additional participants
were recruited, meaning that 80 participants were
randomized.
Statistical Analyses
The statistical analysis plan was recorded prior to data
lock and analysis and is included in the Supplementary
Statistical Analysis Plan. Normality was assessed using
a KolmogorovSmirnov test with additional visual
inspection of box plots. Data for continuous variables
are presented as mean  SD for normally distributed
148data and median (interquartile range) for
nonnormally distributed data. Categorical data are
expressed as numbers (%). Continuous variables were
compared using analysis of variance (if normally
distributed) or MannWhitney U test (if not normally
distributed), whereas categorical variables were
analyzed using the c2 test or the Fisher exact test if
appropriate. Correlation analysis was performed for
changes in LVMI. The primary efficacy analysis was
analyzed as described above and is presented as the
between-group difference in change in LVMI between
baseline and 12 months; the 95% confidence interval
for the treatment effects have also been presented.
Follow-up was on a “modified intention-to-treat” basis,
whereby all participants were invited for follow-up
and included in the analysis even if study medication
had been discontinued unless a participant underwent
kidney transplantation or died. Patients without a
follow-up CMRI were not included in the final analysis
of the primary outcome but were included in a missing-
cases sensitivity analysis. The number of patients not
completing the second CMRI scan study was unex-
pectedly high. A further pre-specified analysis was
performed using imputed LVMI in patients unable to
have a second CMRI scan (5 imputations per completed
case). After establishing that the data were missing at
random, a further analysis was performed using mul-
tiple imputation for the missing values for change in
LVMI. The influence of pre-specified covariates (pre-
dialysis systolic BP, ultrafiltration volumes, and base-
line LVMI) on the primary outcome was assessed using
analysis of covariance. Secondary outcome analyses
were conducted in a similar manner. Between-group
differences in urate, FMD, pulse wave velocity
(PWV), and AIx were assessed using a repeated-
measures analysis of variance. A 2-sided P value
of <0.05 was considered statistically significant for all
analyses. All analyses were undertaken in SPSS version
23.0 (IBM Corporation, Armonk, NY).RESULTS
Between January 2014 and June 2015, a total of 96
patients who were undergoing regular hemodialysis
consented to participate in this trial. Of those, 16
participants were not eligible for randomization
following screening; 80 participants were therefore
randomized. Figure 1 shows the study Consolidated
Standards of Reporting Trials (CONSORT) diagram.
There were 26 participant withdrawals during the trial
(15 in the placebo group and 11 in the allopurinol
group). This included 4 deaths on the placebo arm and
2 on the allopurinol arm. An additional 5 participants
(3 on placebo and 2 on allopurinol) withdrew fromKidney International Reports (2021) 6, 146–155
Assessed for eligibility (n=96) 
Excluded (n=16) 
* Not meeting inclusion criteria  
(n=9: excluded by echocardiogram       
findings=8, in another trial=1) 
* Declined to participate (n=2) 
* Transplanted during screening period (n=2) 
* Unable to tolerate MRI (n=3) 
Analyzed (n=25) 
♦ Excluded from analysis (n=0)
* Lost to follow-up (n=0) 
* Discontinued intervention and withdrawn from   
study (n=15: death=5, transplanted=5, consent 
withdrawn=3, adverse effects (rash)=1, 
frailty=1) 
* Discontinued intervention but remained in 
study for intention to treat (n=3: recurrent 
gout=1, deranged liver function tests=1, patient 
choice=1)
Allocated to and received placebo (n=40) 
* Lost to follow-up (n=0) 
* Discontinued intervention and withdrawn 
from study (n=11: death=2, transplanted=6, 
consent withdrawn=1, frailty=1, new MRI 
contraindication=1) 
* Discontinued intervention but remained in 
study for intention to treat n=2 (persistent rash 
= 1, gastrointestinal symptoms = 1) 
Allocated to and received allopurinol (n=40) 
Analyzed (n=28) 
♦ Excluded from analysis (n=1: protocol 
deviation, MRI conducted on dialysis day)
Randomized (n=80) 
Figure 1. Consolidated Standards of Reporting Trials (CONSORT) diagram. MRI, magnetic resonance imaging.
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intention-to-treat analysis. One participant on the
active treatment arm was excluded from all analysis
prior to unblinding because of a protocol deviation
whereby the participant’s CMRI was conducted
immediately pre-dialysis, rather than on a post-
dialysis day.
Baseline characteristics for all participants by their
treatment allocation are shown in Table 1. Participants
were well matched in terms of age, sex, renal replace-
ment therapy history, cause of ESKD, and past medical
history. Medication use was similar between groups
(Supplementary Table S1). There was no difference in
serum urate between study groups at baseline (urate
allopurinol group: 365  86 mmol/l; placebo: 365  88
mmol/l; P ¼ 0.9).
Primary Outcome
In this trial, 300 mg of allopurinol after dialysis for 12
months was not associated with a significant reductionKidney International Reports (2021) 6, 146–155in LVMI. In a modified intention-to-treat analysis, in
participants who completed both CMRI scans,
following 12 months of treatment the mean change in
LVMI with allopurinol was þ1.6  11.0 g/m2,
compared with þ3.6  10.4g/m2 with placebo (be-
tween-group difference: 2.1g/m2; 95% confidence
interval [CI]: 7.9 to 3.8g/m2; P ¼ 0.49). Adjustment
for pre-specified factors that may influence LVMI
change in this population (pre-dialysis systolic BP,
ultrafiltration volumes, and baseline LVMI) did not
have a significant impact on these results.
In a further intention-to-treat analysis using imputa-
tion to account for missing CMRI data in patients unable
to have a second CMRI scan, once again there was no
significant difference between treatment groups (change
in LVMI placebo: þ2.7; 95% CI: 6.0 to þ14.1) g/m2;
allopurinol: þ2.3; 95% CI: 6.0 to þ14.4; P ¼ 0.88.
Similarly, there was no difference in change in end-
diastolic volume (EDV), end-systolic volume (ESV), or
ejection fraction between treatment groups (Table 2).149
Table 1. Study baseline clinical parameters
Baseline characteristics Allopurinol (n [ 39) Placebo (n [ 40) P value
Age, yr 57.8  11.6 58.0  13.0 0.90
Sex, % male 64.1 57.5 0.55
Ethnicity
White/Caucasian, % 95 100 0.35
Other, % 5 0
Presystolic BP, mm Hg 139  21 144  25 0.301
Prediastolic BP, mm Hg 68  12 75  13 0.05
Ultrafiltration volume, L 1.5 (1.3–2.5) 1.7 (1.0–2.4) 0.84
Weight, kg 73 (60–84) 78 (67–96) 0.16
BMI, kg/m2 26.1(21.9 - 29.3) 28.7 (22.6–34.8) 0.24
RRT, mo 32 (16–100) 34 (20–78) 0.90
Duration hemodialysis, mo 30 (15–61) 29 (16–51) 0.90
Dialysis access, %
Fistula or graft 87.2 82.5 0.18
Line 12.8 17.5
Primary renal disease, %
Diabetic nephropathy 20.5 17.5 0.54
ADPKD 15.4 17.5 0.80
Glomerulonephritis 23.1 17.5 0.74
Renovascular disease 5.1 5.0 0.90
Chronic pyelonephritis 0 7.5 0.05
Other/unknown 33.4 32.5 0.90
Hypertension 2.6 2.5 0.57
Past medical history, %
Diabetes 25.6 22.5 0.90
Hypertension 69.2 70.0 0.90
Cerebrovascular disease 23.1 20.0 0.74
Peripheral vascular disease 23.1 12.5 0.22
Ischemic heart disease 17.9 22.5 0.62
Dyslipidemia 43.6 35.0 0.43
Smoking history, %
Ex/current 61.5 52.5 0.45
Never 38.5 47.5
Hemoglobin, g/dla 11.8 (11.3–12.6) 111 (10.5–11.8) 0.41
URR, %b 75.8  5.3 73.8  7.7 0.20
Albumin, g/La 35 (32–36) 33 (30–36) 0.08
Urate, mmol/La 365  86 365  88 0.90
Phosphate, mmol/La 1.61  0.45 1.74  0.51 0.22
LVM, g 123.8  45.8 121.3  44.5 0.80
LVMI, g/m2 63.0 (54.2–79.8) 58.5 (45.8–78.5) 0.25
EDV, ml 150.0 (124.7–174.6) 143.5 (126.6–172.6) 0.90
ESV, ml 59.3 (40.6–73.4) 61.3 (51.5–75.6) 0.83
Ejection fraction, % 60.4  8.5 59.2  8.8 0.53
Post-systolic BP, mm Hg 126 (113–138) 123 (110–149) 0.88
Post-diastolic BP, mm Hg 65  13 69  15 0.15
24-h systolic BP, mm Hgc 120  18 128  23 0.35
24-h diastolic BP, mm Hgc 71  13 74  14 0.46
FMD–baseline cuff, % changed 4.1  2.7 3.9  3.8 0.87
FMD–baseline GTN, % changed 11.7  6.0 13.8  3.8 0.95
PWV, m/se 7.6  1.6 7.7  2.2 0.82
AIx, %f 23.9  10.0 24.4  17.0 0.92
AIx, augmentation indices; ADPKD, autosomal dominant polycystic kidney disease; BMI, body mass index; BP, blood pressure; EDV, end-diastolic volume; ESV, end-systolic volume;
FMD, flow-mediated dilation; GTN, glyceryl trinitrate; PVW, pulse wave velocity; LVM, left ventricular mass; LVMI, left ventricular mass index; RRT, duration of time receiving renal
replacement therapy (in months); URR, urea reduction ratio.
aData available for 78 participants.
bData available for 75 participants.
cData available for 26 participants.
dData available for 34 participants.
eData available for 31 participants.
fData available for 35 participants.
Data are presented as mean  SD or as median (interquartile range) if nonparametric.
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Table 2. Comparison of the change in parameters by treatment groups
Parameter change Allopurinol (n [ 28) Placebo (n [ 25) Between-group difference (95% CI) P
Change in LVMI at 12 mo, g/m2 1.6  11.0 3.6  10.4 –2.1 (–7.9 to 3.8) 0.49
Change in LVM at 12 mo, g –0.7 –(10.2 to 11.9) 1.0 (–5.3 to 14.6) –4.2 (–14.7 to 6.2) 0.49
Change in LVEF at 12 mo, % –1.3  5.6 –1.0  7.2 –0.3 (–3.9 to 3.3) 0.86
Change in ESV at 12 mo, ml 4.7  1 8.2 3.0  22.8 1.7 (–9.8 to 13.2) 0.77
Change in EDV at 12 mo, ml 6.1  28.0 0.8  27.7 5.3 (–10.1 to 20.7) 0.49
Change in FMD response to hyperemia at 9 mo, %a 0.0  2.9 –2.6  4.0 2.6 (–1.0 to 6.3) 0.12
Change in FMD response to hyperemia at 12 mo, %b –0.4 (–2.1 to –0.0) 1.4 (–3.4 to 5.2) –2.7 (–7.6 to 2.3) 0.55
Change in FMD response to GTN at 9 mo, %a –1.5  6.0 –4.9  4.3 3.4 (–1.7 to 8.6) 0.19
Change in FMD response to GTN at 12 mo, %b –2.3  5.2 –0.4  4.9 –1.5 (–6.7 to 3.6) 0.54
Change in radial AIx at 9 mo, %c –4.0 (–12.0 to –2.0 0.0 (–7.0 to 12) –10.5 (–26.9 to 5.8) 0.09
Change in radial AIx at 12 mo, %c –1.4  8.8 3.6  9.9 4.9 (–4.0 to 13.9) 0.26
Change in PWV at 9 mo, m/sd 0.9  2.7 0.5  1.8 –0.4 (–2.8 to 2.0) 0.72
Change in PWV at 12 mo, m/sa 1.1  1.7 0.7  2.0 –0.3 (–2.3 to 1.7) 0.72
Change in mean systolic 24-h BP at 12 mo, mm Hge 8.3  13.3 8.8  19.8 –0.5 (–30.7 to 29.7) 0.9
Change in mean diastolic 24-h BP at 12 mo, mm Hge 2.3  5.6 1.0  11.6 –1.5 (–16.3 to 13.2) 0.85
Change in mean pre-dialysis systolic BP at 12 mo, mm Hg 3.7  17.1 0.9  21.8 –0.28 (–13.5 to 8.0) 0.60
Change in mean pre-dialysis diastolic BP at 12 mo, mm Hg 1.7  10.5 0.2  13.3 –1.5 (–16.3 to 13.2) 0.65
AIx, augmentation indices; BP, blood pressure; EDV, end-diastolic volume; ESV, end-systolic volume; FMD, flow-mediated dilation; GTN, glyceryl trinitrate; PVW, pulse wave velocity;
LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index.
aResults available for 18 participants.
bResults available for 19 participants.
cResults available for 20 participants.
dResults available for 17 participants.
eResults available for 8 participants.
E Rutherford et al.: A Randomized Trial of Allopurinol in Hemodialysis CLINICAL RESEARCHIn the 18 patients who underwent FMD, there was
no statistically significant change in response to hy-
peremia at 9 or 12 months (9-months change in FMD
response to hyperemia: allopurinol: þ0.0% (2.9%);
placebo: 2.6% (4.0%); treatment effect: 2.6%; 95%
CI: 1.0% to 6.3%; P ¼ 0.12). Change in response to
glyceryl trinitrate at 12 months was negatively corre-
lated with change in LVMI (Pearson’s R ¼ 0.601, P ¼
0.007). This and other correlations of change in LVMI
with other parameters are shown in Table 3.
Allopurinol had no statistically significant effect on
AIx at 9 or 12 months. There was no difference inTable 3. Correlations between change in LVMI and other
parameters
Parameter Change in LVMI
D FMD cuffa R ¼ 0.197
P ¼ 0.42
D FMD GTNa R ¼ 0.601
P ¼ 0.007
D AIxb R ¼ 0.188
P ¼ 0.39
D PWVc R ¼ 0.105
P ¼ 0.68
D EDVd R ¼ 0.525
P < 0.001
D Uratee R ¼ 0.287
P ¼ 0.046
AIx, augmentation index; EDV, end-diastolic volume; FMD, flow-mediated dilation; GTN,
glyceryl trinitrate; LVMI, left ventricular mass index; PWV, pulse wave velocity.
aData available for 19 participants.
bData available for 23 participants.
cData available for 18 participants.
dData available for 53 participants.
eData available for 49 participants.
Kidney International Reports (2021) 6, 146–155change in pulse wave velocity between treatment
groups, which changed minimally over the course of
the trial (Table 2).
In this trial, there was no evidence that allopurinol
had any effect on BP. A total of 26 participants un-
dertook 24-hour ambulatory BP monitoring at baseline,
with 8 participants completing follow-up measure-
ments (4 on allopurinol and 4 on placebo). Results from
these participants were in line with the changes seen in
pre-dialysis BP, which was available for all partici-
pants, in which changes in BP between treatment
allocation groups were no different from each other
(Table 2).
Change in Urate
A modest reduction in mean pre-dialysis urate was
achieved in the allopurinol group when compared to
placebo (Figure 2, Table 4). The difference in mean
urate from baseline at month 12 in the placebo arm
was þ 21.0  110.0 mmol/l, whereas with allopurinol, a
mean reduction in urate of 42.6  82.8 mmol/l was
achieved (P ¼ 0.013); treatment effect: 63.6; 95%
CI: 114.2 to 13.0) mmol/l. This equated to a median
reduction in urate of 18.5 mmol/L (interquartile
range: 26.8% to 0.0%) in subjects receiving
allopurinol.
Safety
Allopurinol 300 mg was well tolerated. The number of
adverse events (AEs) in this trial was in keeping with
other trials within the ESKD population, with 93.75%151
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Figure 2. Change in serum urate with treatment allocation. Figure shows change in mean urate at visits throughout the study (visit 2 at baseline,
visit 4 at 6 weeks, visit 5 at 6 months, visit 6 at 9 months, and visit 7 at 12 months).
CLINICAL RESEARCH E Rutherford et al.: A Randomized Trial of Allopurinol in Hemodialysisof randomized participants having at least 1 event.26–28
Table 5 provides a summary of serious AEs and re-
actions, and a full breakdown of all study AEs is
included in Supplementary Table S2. The number of
AEs was similar between treatment groups, and there
was no significant increase in gastrointestinal or skin
and subcutaneous tissue disorders in the allopurinol
arm.
Per Protocol Analysis
Five participants completed their second CMRI but
were taken off study medication during the course of
the study (3 on placebo and 2 on allopurinol). A per
protocol analysis of completed cases only was per-
formed with the above participants excluded. In this
completed cases analysis, allopurinol was not associated
with reduction of LVMI when compared to placebo.
Mean change in LVMI with allopurinol þ1.6 ( 11.1),
compared to þ 3.7 (10.7) with placebo (P ¼ 0.508).Table 4. Comparison of urate values by treatment groups
Urate measurement Placebo Allopurinol
Baseline urate,
mmol/l
365; 95% CI ¼ 338392
n ¼ 40
365; 95% CI ¼ 338392
n ¼ 38
Visit 4 urate,
mmol/l
362; 95% CI ¼ 334389
n ¼ 37
318; 95% CI ¼ 294342
n ¼ 38
Visit 5 urate,
mmol/l
357; 95% CI ¼ 332382
(n ¼ 30)
327; 95% CI ¼ 295360
n ¼ 32
Visit 6 urate,
mmol/l
375; 95% CI ¼ 341409
(n ¼ 28)
313; 95% CI ¼ 285341
n ¼ 32
Visit 7 urate,
mmol/l
376; 95% CI ¼ 336417
n ¼ 25
317; 95% CI ¼ 283351
n ¼ 30
CI, confidence interval; n, number of patients in each group.
152DISCUSSION
This trial is the first clinical trial to consider regression
of LVMI with allopurinol in a population undergoing
regular hemodialysis. Overall, allopurinol 300 mg after
dialysis for 1 year did not regress LVMI when
compared with placebo. Furthermore, there was no
statistically significant effect of allopurinol 300 mg on
BP, FMD, AIx, or pulse wave velocity.
The reduction in urate in this trial was lower than in
previously reported studies in other populations in
which allopurinol regressed LVMI, including in a
population with CKD 3 in which a reduction in urate of
approximately 42% was achieved.17,18,20 In this pre-
vious work, reduction in LVMI has not been directly
correlated with reduction in urate. However, in this
trial, perhaps because of the lower reduction in urate
achieved, change in LVMI over the trial period was
weakly correlated with change in urate from baseline
(Spearman R ¼ 0.287, P ¼ 0.046).
It is, worth noting that in this study, for participants
undergoing FMD, change in response to GTN at 12
months was negatively correlated with change in LVMI
(Pearson R ¼ 0.601, P ¼ 0.007). Although, tradi-
tionally, nitrate-mediated dilation has served as a
control measure, its association with LVMI in this
study is in keeping with work that has shown nitrate-
mediated dilation to be an independent predictor of
cardiovascular disease.29,30
This trial used the modest dose of 300 mg of allo-
purinol to minimize potential increased risks of severe
rash or drug hypersensitivity syndrome associatedKidney International Reports (2021) 6, 146–155
Table 5. Breakdown of unique serious adverse events by treatment
group
MedDRA Coding Allopurinol Placebo Grand totala
1. Adverse events 81 74 155
2. Adverse reactions 15 15 30
3. Serious adverse events 16 28 44
Blood and lymphatic system disorders 1 1
Cardiac disorders 1 1 2
Gastrointestinal disorders 2 4 6
Hepatobiliary disorders 1 1
Immune system disorders 1 1
Infections and infestations 3 3 6
Injury, poisoning, and procedural complications 1 5 6
Metabolism and nutrition disorders 1 1
Musculoskeletal and connective tissue disorders 1 2 3
Neoplasms benign, malignant and unspecified 1 1 2
Nervous system disorders 3 1 4
Respiratory, thoracic, and mediastinal disorders 2 2
Skin and subcutaneous tissue disorders 1 1
Surgical and medical procedures 1 4 5
Vascular disorders 1 2 3
4. Serious adverse reaction 1 1
Skin and subcutaneous tissue disorders 1 1
Grand total 112 118 230
MedDRA, Medical Dictionary for Regulatory Activities.
aRepetitions of the same adverse event for any given participant have been excluded
from this table.
E Rutherford et al.: A Randomized Trial of Allopurinol in Hemodialysis CLINICAL RESEARCHwith the use of allopurinol in patients with significant
kidney function impairment.31 In order to use the
minimal potentially effective dose of allopurinol, an
open-label dose-finding study was conducted prior to
this trial, in which 10 patients undergoing regulat
hemodialysis received increasing doses of allopurinol
after dialysis up to a maximum of 350 mg, with the
intention of stopping escalating doses when a reduction
in urate of 50% was achieved.21 In fact, no patient
achieved a reduction of 50%, and the greatest mean
reduction of urate of around 20% was achieved with
allopurinol 300 mg. This is likely to be because allo-
purinol and its active metabolites are removed by he-
modialysis.32 Allopurinol was given after hemodialysis,
and at this time urate, which is also removed by dial-
ysis, would be at its lowest. However, a 20% reduction
in urate is only a modest reduction. This trial demon-
strated the tolerability of this dose, so in a further trial
it would be reasonable to use a larger dose of allopu-
rinol, potentially titrated to effect on urate.
This study does have several limitations. The study
was classified as an intention-to-treat study, as we
included patients in our final analysis who stopped
study medication during the course of the study.
However, as specified in our study protocol, we were
unable to include patients who had undergone trans-
plantation, had died, or did not have a second CMRI in
our primary outcome analysis as a result of these
missing data. The original power calculation for thisKidney International Reports (2021) 6, 146–155study was based on a 20% drop-out during follow-up;
however, the drop-out rate was higher than anticipated
at 33.8%, which raises the issue of whether the study
might have been underpowered. To explore the effect
of these withdrawals on the overall outcome, a missing
case analysis was performed to confirm that the data
were missing at random. There were no significant
differences in terms of baseline age, sex, baseline
LVMI, ejection fraction, BP, or ultrafiltration volumes
between those that withdrew from the study and those
that completed it.
The fact that the difference in LVMI between the
treatment and placebo groups remained statistically
nonsignificant after using pre-specified multiple
imputation modeling for the missing change in LVMI
values suggests that the lack of treatment effect be-
tween treatment groups is a result of a truly negative
trial and that it is not a result of a type 2 error. Further
supporting the fact that this is a truly negative study
and not simply underpowered is the fact that retro-
spectively re-performing our original power calculation
with adjustment for our baseline data suggests that 42
participants were required to complete the study for
90% power and an a of 0.05. This is significantly fewer
than the 53 participants who completed the study. In
addition, a difference in LVMI was detected in a
similarly designed CMRI study in hemodialysis pa-
tients in which only 44 participants completed final
follow-up.8 This further supports the assertion that the
failure of this study to meet its primary outcome was
not the result of a type 2 error.
Recruitment to this trial proved challenging. In or-
der to maximize the number of potentially eligible
participants, the inclusion criteria were relaxed so that
participants without LVH could participate. This was
not believed to detract from the value of the trial, as
any regression of LVM regardless of any arbitrary cut-
offs for LVH may potentially be beneficial to patient
outcomes.33 However, it is possible that any potential
changes in myocardial mass were smaller and more
difficult to detect with a lower starting mass.20 Putting
this trial in a wider context, despite observational data
consistently associating LVM with reduced survival in
patients requiring hemodialysis,34 a meta-analysis
published after recruitment to our trial was complete
demonstrated no clear association between reduction of
LVM and improved survival in this patient group.5
Therefore, it is unclear whether LVM remains a sur-
rogate marker of future cardiovascular mortality that
should be targeted in clinical trials to improve out-
comes. Furthermore, the CKD-FIX trial has recently
reported showing no benefit of allopurinol on cardio-
vascular or renal outcomes in advanced CKD compared
to placebo.35153
CLINICAL RESEARCH E Rutherford et al.: A Randomized Trial of Allopurinol in HemodialysisIn addition to the limitations discussed above, the
population in this study was not ethnically diverse;
allopurinol may have been less well tolerated in a
group of patients with a different gene pool,36 and in
a more diverse trial population, the effect of the 300
mg dose may have been different. In addition,
although regression of absolute myocardial mass is an
important therapeutic target, this trial was not
designed to quantify any change in character of
myocardial tissue associated with allopurinol.
Adverse fibrotic myocardial remodeling is well
known to contribute to poor outcomes, and, in any
future trial, it would be interesting to characterize
myocardial tissue using emerging non-contrast imag-
ing techniques.37 A larger trial examining the effect
of allopurinol on myocardial structure, composition,
and morbidity and mortality would be of potential
interest.
In conclusion, in this study, compared with placebo,
treatment with allopurinol 300 mg did not regress
LVMI in hemodialysis patients over 1 year of therapy.DISCLOSURE
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